RxDoctor Payments Data

Anthony Hicks, MD

Internal Medicine · Memphis, TNNPI 1225022494

Payments from drug & device makers

$3,380in general payments, 2019–2025

Across 185 payments — averaging $18.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$860
  • GSK$733
  • Lilly USA, LLC$477
  • Abbott$443
  • Bayer$218
  • C2n Diagnostics, LLC$170
  • plus $478 from 9 others

What the payments were for

  • Food & beverage$3,380100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,380 in reported general payments places this provider in the 80th percentile of 2,216 internal medicine providers in Tennessee.

See all internal medicine providers in Tennessee

Medicare billing

Part B allowed, 2024
$9,410
Medicare patients
39
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin82$107,041
Trelegy ElliptaFluticasone/Umeclidin/Vilanter69$80,530
RybelsusSemaglutide51$75,915
KerendiaFinerenone64$71,965
EliquisApixaban50$54,973
OzempicSemaglutide14$30,187
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr34$28,416
TrulicityDulaglutide13$24,422
XareltoRivaroxaban16$22,954
Tresiba Flextouch U-100Insulin Degludec31$15,281
Breo ElliptaFluticasone/Vilanterol11$6,111
LantusInsulin Glargine,hum.Rec.Anlog39$5,434
Albuterol Sulfate HfaAlbuterol Sulfate115$3,499
Levemir FlexpenInsulin Detemir11$3,467
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$3,345

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$733$115,057114 claims
Novo NordiskRybelsus, Ozempic$860$106,10265 claims
BayerKerendia$218$71,96564 claims
PfizerEliquis$46$54,97350 claims
Lilly USA, LLCTrulicity$477$24,42213 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,216 internal medicine providers in Tennessee.

Other internal medicine in Memphis

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →